Effectiveness of ceftazidime–avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia

IntroductionAntimicrobial treatments for carbapenem-resistant Enterobacteriaceae (CRE) bacteremia are limited, with colistin-based regimens being a primary therapy. Ceftazidime–avibactam is an emerging treatment various CRE infections. Our study aimed to assess ceftazidime–avibactam effectiveness compared colistin in patients bacteremia.MethodsThis retrospective, multi-centre included adult treated or colistin, between September 1, 2017 and December 2020, at two tertiary centres Saudi Arabia. The risk of 14-day mortality was recipients versus using Cox multivariable regression, adjusted Pitt score, Charlson index chemotherapy immunosuppressive agents.ResultsIn total, 61 were enrolled; 32 received ceftazidime–avibactam, 29 colistin. lower the group than (hazard ratio [HR] 0.32; 95% confidence interval [CI] 0.10–0.99; p = 0.049), while crude did not differ antibiotics (HR, 0.59; CI 0.21–1.66; 0.32). clinical success rate higher use (46.8% 20.4%, respectively; 0.047).ConclusionCeftazidime–avibactam associated bacteremia.